Drägerwerk stock hits fresh 52-week high as investors focus on recent margin progress

Drägerwerk AG & Co. KGaA (ISIN DE0005550636) stock extended its recent run on August 13, 2026, with the preferred shares touching a new 52-week high of €114.20 and showing a year-to-date gain of 63.40 percent, according to a market snapshot for Drägerwerk preferred shares. This performance places Drägerwerk among the stronger movers in the European mid-cap industrial and medical-technology space for 2026.

Strong price trend and 52-week high

Per a real-time overview of Drägerwerk segment and regional data from a market portal on August 13, 2026, the ordinary shares last traded at €85.00 on Tradegate, down 0.70 percent on the day but still up 1.90 percent since January 1, 2026. This combination of a minor daily setback and a positive year-to-date trend underscores that the stock’s broader trajectory remains constructive even when individual sessions are more muted.

The preferred share class shows an even more pronounced picture. A same-day performance overview reports that Drägerwerk AG & Co. KGaA preferred shares reached a new annual and 52-week high at €114.20 on August 13, 2026, with a gain of 0.71 percent for the session and a year-to-date increase of 63.40 percent. In other words, the preferred shares are now trading more than €28 above the ordinary-share quote, and the 63.40 percent gain since the start of the year highlights investors’ willingness to pay a premium for the preferred line in the current market.

Recent fundamentals and profitability context

The strong share performance in 2026 comes against the backdrop of Drägerwerk’s recent financial reports, which have shown improving profitability from the medical technology and safety segments. In its latest available interim reporting period covering 2026 and referenced in current market data tools, Drägerwerk reported that segment results in core medical and safety businesses benefited from higher utilization of installed devices and disciplined cost control, helping operating earnings and margins improve versus the prior year period. While the exact figures are not detailed in the same market snapshots, the commentary points to earnings growth and margin recovery after more challenging years earlier in the decade.

Historically, the company’s fiscal 2023 performance, cited in background sections of current financial tools, showed that Drägerwerk had already begun to stabilize revenue and earnings after pandemic and supply-chain disruptions. For example, in fiscal 2023 Drägerwerk generated clearly positive operating earnings and improved cash flow compared with 2022, setting a base for the subsequent ramp in 2024 and 2025. These historical numbers now serve primarily as a comparison point and are not the main driver of the valuation on August 13, 2026, but they help explain why the stock had room to re-rate as newer, stronger quarters arrived.

Looking at 2026, consensus commentary reflected in current ratings overviews suggests that analysts expect Drägerwerk to continue expanding margins through better product mix in anesthesia, ventilation, and patient monitoring, as well as through digital services linked to hospital infrastructure. The strong move in the preferred shares to €114.20 and the 63.40 percent year-to-date gain are consistent with a scenario where earnings per share and return on capital are anticipated to improve versus the prior fiscal year, even though the precise consensus numbers are not broken out in the short market snapshots.

Valuation and investor interpretation

From an investor’s perspective, the price pattern on August 13, 2026 supports the view that Drägerwerk stock is benefiting from a combination of operational progress and a search for quality industrial and healthcare names in Europe. The ordinary shares at €85.00 with a 1.90 percent rise since January 1, 2026 and the preferred shares at €114.20 with a 63.40 percent year-to-date increase suggest that the market is assigning a higher valuation to the more liquid or more favored line, while still keeping the ordinary shares in an upward channel.

The quantified spread between ordinary and preferred shares is notable. With the preferred line trading €29.20 above the ordinary shares on August 13, 2026, investors who bought into Drägerwerk’s preferred shares earlier in the year have seen significantly higher gains than holders of the ordinary shares. This spread also reflects different investor bases and index inclusion patterns, since some institutional mandates prefer preferred shares where liquidity and dividend policies align with fund requirements.

In relative terms, the 63.40 percent year-to-date gain on Drägerwerk preferred shares compares favorably to many broader European stock indices, where single-digit or low double-digit performance is more common in 2026. That contrast indicates that, within the mid-cap medical-technology and safety-equipment universe, Drägerwerk is currently one of the more dynamic names, at least in price terms. Investors who focus on momentum and improving fundamentals may therefore continue to follow the stock as long as the company delivers on its earnings and margin expectations.

Medical and safety technology portfolio

A central reason why Drägerwerk remains relevant to global healthcare and industrial customers is its portfolio of medical and safety technology. The company’s offerings span critical care ventilation devices, anesthesia workstations, patient monitoring systems, and related accessories for hospitals and clinics. These devices are frequently integrated into digital platforms that allow hospital staff to monitor patient status and equipment performance in real time, a capability that has become more important as healthcare systems manage higher patient volumes with limited staff.

Drägerwerk also supplies safety technology to industrial clients, including gas-detection devices, breathing apparatus and protective equipment for fire services, and safety monitoring solutions for chemical plants and energy infrastructure. These products contribute to recurring revenue streams through equipment replacement, maintenance contracts, and digital monitoring services. As industrial clients seek higher safety standards and regulatory compliance, the demand for such equipment can support long-term revenue visibility for Drägerwerk.

Within this broad portfolio, ventilators and anesthesia systems are particularly emblematic of Drägerwerk’s positioning. These devices link directly to intensive care units and operating theaters, where reliability and accurate monitoring are critical. Hospital customers often evaluate suppliers based on performance data, support, and integration with existing hospital information systems, and Drägerwerk’s ability to meet these requirements underpins its role as a core supplier in many markets.

Stock level and investor takeaway

As of August 13, 2026, Drägerwerk ordinary shares trade at €85.00 on Tradegate, with a modest daily decline of 0.70 percent but a positive year-to-date performance of 1.90 percent. The preferred shares, by contrast, sit at a 52-week high of €114.20 with a 0.71 percent gain on the day and a strong 63.40 percent increase since January 1, 2026. For investors, these figures highlight both the premium attached to the preferred shares and the market’s constructive view of Drägerwerk’s recent operational developments and earnings outlook.

Fact box

Company: Drägerwerk AG & Co. KGaA
ISIN: DE0005550636
Ticker: DRW
Exchange: Xetra and regional German exchanges
Price (as of August 13, 2026, intraday Tradegate): €85.00 for ordinary shares; €114.20 for preferred shares
Sector / Industry: Medical technology and safety equipment
Index membership: German mid-cap and sector indices